| Literature DB >> 34729993 |
Gaofeng Lin1,2, Tong Zou1,2, Min Dong1, Junpeng Liu1, Wen Cui1, Jiabin Tong1, Haifeng Shi1, Hao Chen1, Jia Chong1, You Lyu1, Sujuan Wu1, Zhilei Wang1, Xin Jin1, Xu Gao1, Lin Sun1, Yimei Qu1, Jiefu Yang1,2.
Abstract
Background Subclinical infection of cardiac implantable electronic devices (CIEDs) is a common condition and increases the risk of clinical infection. However, there are limited studies focused on risk stratifying and prognostic analysis of subclinical CIED infection. Methods and Results Data from 418 consecutive patients undergoing CIED replacement or upgrade between January 2011 and December 2019 were used in the analysis. Among the patients included, 50 (12.0%) were detected as positive by bacterial culture of pocket tissues. The most frequently isolated bacteria were coagulase-negative staphylococci (76.9%). Compared with the noninfection group, more patients in the subclinical infection group were taking immunosuppressive agents, received electrode replacement, or received CIED upgrade and temporary pacing. Patients in the subclinical infection group had a higher PADIT (Prevention of Arrhythmia Device Infection Trial) score. Univariable and multivariable logistic regression analysis found that use of immunosuppressive agents (odds ratio [OR], 6.95 [95% CI, 1.44-33.51]; P=0.02) and electrode replacement or CIED upgrade (OR, 6.73 [95% CI, 2.23-20.38]; P=0.001) were significantly associated with subclinical CIED infection. Meanwhile, compared with the low-risk group, patients in the intermediate/high-risk group had a higher risk of subclinical CIED infection (OR, 3.43 [95% CI, 1.58-7.41]; P=0.002). After a median follow-up time of 36.5 months, the end points between the subclinical infection group and noninfection group were as follows: composite events (58.0% versus 41.8%, P=0.03), rehospitalization (54.0% versus 32.1%, P=0.002), cardiovascular rehospitalization (32.0% versus 13.9%, P=0.001), CIED infection (2.0% versus 0.5%, P=0.32), all-cause mortality (28.0% versus 21.5%, P=0.30), and cardiovascular mortality (10.0% versus 7.6%, P=0.57). Conclusions Subclinical CIED infection was a common phenomenon. The PADIT score had significant value for stratifying patients at high risk of subclinical CIED infection. Subclinical CIED infection was associated with increased risks of composite events, rehospitalization, and cardiovascular rehospitalization.Entities:
Keywords: bacterial culture; cardiac implantable electronic devices; prognosis; risk stratifying; subclinical infection
Mesh:
Substances:
Year: 2021 PMID: 34729993 PMCID: PMC8751915 DOI: 10.1161/JAHA.121.022260
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Microbiology of subclinical cardiac implantable electronic device infection (n=52).
CoNS indicates coagulase‐negative staphylococci.
Baseline Characteristics of 418 Patients
| Total, N=418 | Subclinical infection group, n=50 | Noninfection group, n=368 |
| |
|---|---|---|---|---|
| Age, y | 78.1±9.7 | 76.5±9.5 | 78.3±9.6 | 0.22 |
| Men | 222 (53.1) | 33 (66.0) | 189 (51.4) | 0.05 |
| BMI, kg/m2 | 24.7±3.7 | 24.9±3.6 | 24.7±3.7 | 0.67 |
| Comorbidities | ||||
| CKD | 120 (28.7) | 11 (22.0) | 109 (29.6) | 0.26 |
| COPD | 20 (4.8) | 1 (2.0) | 19 (5.2) | 0.49 |
| Hypertension | 303 (72.5) | 37 (74.0) | 266 (72.3) | 0.80 |
| Coronary artery disease | 155 (37.1) | 18 (36.0) | 137 (37.2) | 0.87 |
| Atrial fibrillation | 169 (40.4) | 20 (40.0) | 149 (40.5) | 0.94 |
| Heart failure | 73 (17.5) | 12 (24.0) | 61 (16.6) | 0.20 |
| Diabetes | 128 (30.6) | 17 (34.0) | 111 (30.2) | 0.58 |
| Malignancies | 31 (7.4) | 5 (10.0) | 26 (7.1) | 0.40 |
| Drugs | ||||
| Anticoagulants | 34 (8.1) | 6 (12.0) | 28 (7.6) | 0.27 |
| Antiplatelet drugs | 197 (47.1) | 27 (54.0) | 170 (46.2) | 0.30 |
| Immunosuppressive agents | 7 (1.7) | 3 (6.0) | 4 (1.1) | 0.04 |
| CIED indications | 0.20 | |||
| SSS | 252 (60.3) | 29 (58.0) | 223 (60.6) | |
| AVB | 154 (36.8) | 18 (36.0) | 136 (37.0) | |
| HFrEF | 8 (1.9) | 3 (6.0) | 5 (1.4) | |
| Ventricular tachycardia | 4 (1.0) | 0 (0) | 4 (1.1) | |
| CIED types | 0.18 | |||
| Single‐chamber PM | 70 (16.7) | 11 (22.0) | 69 (18.8) | |
| Dual‐chamber PM | 321 (76.8) | 35 (70.0) | 286 (77.7) | |
| ICD | 8 (1.9) | 1 (2.0) | 7 (1.9) | |
| CRT | 9 (2.2) | 3 (6.0) | 6 (1.6) | |
| Implantation time, mo | 125.2±58.3 | 127.8±58.2 | 124.8±58.3 | 0.74 |
| No. of prior procedures | 1.0 [1.0–1.0] | 1.0 [1.0–2.0] | 1.0 [1.0–1.0] | 0.45 |
| Electrode replacement or CIED upgrade | 18 (4.3) | 8 (16.0) | 10 (2.7) | <0.001 |
| Temporary pacing | 31 (7.4) | 8 (16.0) | 24 (6.5) | 0.04 |
| Perioperative fever | 18 (4.3) | 4 (8.0) | 14 (3.8) | 0.25 |
| Postoperative hematoma | 9 (2.2) | 2 (4.0) | 7 (1.9) | 0.29 |
| PADIT score | 1.0 [1.0–4.0] | 2.0 [1.0–4.0] | 1.0 [1.0–4.0] | 0.002 |
Data are expressed as n (%), mean±SD, or median [interquartile range]. AVB indicates atrioventricular block; BMI, body mass index; CIED, cardiac implantable electronic device; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; HFrEF, heart failure with reduced ejection fraction; ICD, implantable cardioverter‐defibrillator; PADIT, Prevention of Arrhythmia Device Infection Trial; PM, pacemaker; and SSS, sick sinus syndrome.
Univariable and Multivariable Logistic Analysis of Risk Factors Associated With Subclinical CIED Infection
| Risk factors | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| |
| Heart failure | 1.59 (0.79–3.22) | 0.20 | 1.03 (0.45–2.38) | 0.94 |
| COPD | 0.38 (0.05–2.86) | 0.34 | ||
| CKD | 0.67 (0.33–1.36) | 0.27 | ||
| Diabetes | 1.19 (0.64–2.23) | 0.58 | ||
| Malignancy | 1.46 (0.53–4.00) | 0.46 | ||
| Antiplatelet drugs | 1.37 (0.76–2.47) | 0.30 | ||
| Anticoagulants | 1.66 (0.65–4.22) | 0.29 | ||
| Immunosuppressive agents | 5.81 (1.26–26.76) | 0.02 | 6.95 (1.44–33.51) | 0.02 |
| CIED types | 2.38 (0.74–7.59) | 0.15 | 1.01 (0.23–4.41) | 0.99 |
| No. of prior procedures | 1.32 (0.68–2.55) | 0.42 | ||
| Electrode replacement or CIED upgrade | 6.82 (2.55–18.23) | <0.001 | 6.73 (2.23–20.38) | 0.001 |
| Temporary pacing | 2.33 (0.95–5.74) | 0.07 | 1.19 (0.40–3.56) | 0.75 |
| Perioperative fever | 2.20 (0.69–6.96) | 0.18 | 2.29 (0.69–7.67) | 0.18 |
| Postoperative hematoma | 2.15 (0.43–10.64) | 0.35 | ||
| PADIT score | 3.43 (1.58–7.41) | 0.002 | ||
CIED indicates cardiac implantable electronic devices; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; OR, odds ratio; and PADIT, Prevention of Arrhythmia Device Infection Trial.
CIED type was categorized as single‐/double‐chamber pacemaker and implantable cardioverter‐defibrillator/cardiac resynchronization therapy.
Number of prior procedures was categorized as 1 time and ≥2 times.
PADIT score was categorized as low risk and intermediate/high risk.
Figure 2Follow‐up of clinical events between the subclinical infection group (SIG) and noninfection group (NIG).
A, The rate of composite events. B, The rate of cardiac implantable electronic device (CIED) infection. C, The rate of all‐cause mortality. D, The rate of cardiovascular mortality. E, The rate of rehospitalization. F, The rate of cardiovascular rehospitalization.
Characteristics of 3 Patients With CIED Infection
| Patient 1 | Patient 2 | Patient 3 | |
|---|---|---|---|
| Age, y | 83 | 72 | 63 |
| Sex | Male | Male | Male |
| CIED types | Dual‐chamber PM | CRT | Dual‐chamber PM |
| No. of prior procedures | 2 | 3 | 2 |
| Time from last procedure, mo | 41 | 4 | 49 |
| PADIT score | 4 | 9 | 5 |
| Clinical presentation | Pocket infection | Pocket infection | Pocket infection |
| Culture result during CIED revision |
| Negative | Negative |
| Culture result from infected pocket |
| Negative | Negative |
CIED indicates cardiac implantable electronic device; CRT, cardiac resynchronization therapy; PADIT, Prevention of Arrhythmia Device Infection Trial; and PM, pacemaker.